Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

NCT01342172 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT01342172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01342172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2011
Completion date
June 30, 2013
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder neoplasms